Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male, ages 18-68~* Serum total T less than or equal to 275 ng/dL~Exclusion Criteria:~* Significant intercurrent disease of any type, in particular, liver, kidney or heart disease, uncontrolled diabetes mellitus or psychiatric illness.~* Abnormal prostate digital rectal examination, elevated prostate-specific antigen (PSA), American Urological Association (AUA) symptom score of \>15, and/or history of prostate cancer.~* Hematocrit of \<35 or \>50%~* Body mass index (BMI) \>36~* Serum transaminases \> 2 times upper limit of normal or serum bilirubin \> 2.0 mg/dL

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- All study participants (Type: EXPERIMENTAL): Treatment Period 1: Three capsules each containing 100 mg testosterone (T) as testosterone undecanoate (TU), twice daily (BID) for 7 days.~Treatment Period 2: Two capsules each containing 200 mg T as TU and testosterone enanthate (TE), BID for 7 days.~Treatment Period 3: Two capsules each containing 100 mg T as TU, BID for 8 days.~Treatment Period 4: Two capsules each containing 150 mg T as TU and TE, BID for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).